IP Library Granted Patent US 10,450,317
Granted Patent B2
US 10,450,317 · App. 15/736,345 · Granted Oct 22, 2019

Notch pathway signaling inhibitor compounds

Inventors: Julia Marie Clay (Indianapolis, IN); Albert Edge (Brookline, MA); Philip Arthur Hipskind (New Palestine, IN); John C. Gill (Boston, MA); Bharvin Kumar Patel (Carmel, IN); Helmuth Hendrikus Gerardus Van Es (Virac, FR); Aaron D. Wrobleski (Indianapolis, IN); Gaiying Zhao (Carmel, IN)
Assignees: Eli Lilly and Company; Audion Therapeutics
C07D487/04A61P27/16A61P35/00A61P35/02C07D471/14C07D487/14C07B2200/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,450,317
App. No.
15/736,345
Granted
Oct 22, 2019
Kind
B2
Abstract

The present invention provides the following compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing said compounds useful as a Notch pathway signaling inhibitor for the treatment of named cancers, sensorineural hearing loss caused by auditory hair cell loss, and inducing auditory hair cell generation.

Claims (14)

1. A compound of the structure:

or a pharmaceutically acceptable salt thereof.

2. A compound of the structure:

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4. A method of treating colorectal cancer in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

5. A method of treating sensorineural hearing loss caused by auditory hair cell loss in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

6. A method of inducing auditory hair cell generation in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising the compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8. A method of treating colorectal cancer in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 2 , or a pharmaceutically acceptable salt thereof.

9. A method of treating sensorineural hearing loss caused by auditory hair cell loss in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of the compound of claim 2 , or a pharmaceutically acceptable salt thereof.

10. A method of inducing auditory hair cell generation in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of the compound of claim 2 , or a pharmaceutically acceptable salt thereof.

11. A substantially pure diastereomer of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

12. A substantially pure diastereomer of the compound of claim 2 , or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2017
From: EDGE, ALBERT; GILL, JOHN C.; VAN ES, HELMUTH HENDRIKUS GERARDUS
To: AUDION THERAPEUTICS
Reel/Frame 044395/0374 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2017
From: CLAY, JULIA MARIE; HIPSKIND, PHILIP ARTHUR; PATEL, BHARVIN KUMAR; WROBLESKI, AARON D.; ZHAO, GAIYING
To: ELI LILLY AND COMPANY
Reel/Frame 044395/0535 →
Continuity (2)
Provisional Application 62189393 · Jul 7, 2015
Related Publication 20180148456A1 · May 31, 2018